BioCentury | Dec 18, 2006
Company News

Celmed, Kiadis deal

...companies completed their previously announced merger to form Kiadis Pharma B.V. (see BioCentury, Dec. 4). Celmed Biosciences Inc....
BioCentury | Dec 4, 2006
Company News

Celmed, Kiadis deal

...Kiadis will acquire cancer company Celmed for an undisclosed amount of stock. Celmed's pipeline includes TH9402...
...its BioSelact screening technology to identify kinase inhibitors for cancer. Financial details were not disclosed. Celmed Biosciences Inc....
BioCentury | Feb 27, 2006
Company News

Celmed management update

Celmed BioSciences Inc. , Montreal, Quebec Business: Autoimmune, Cancer Promoted: Mark Kaufmann to president and CEO from COO and VP of corporate development Retired: Andre de Villers as president and CEO, while remaining a director WIR...
BioCentury | Feb 22, 2006
Company News

Celmed names Kaufmann CEO

...Cancer and autoimmune company Celmed (Montreal, Quebec) promoted Mark Kaufmann to president and CEO from COO...
...VP of corporate development. He replaces Andre de Villers, who retired but will remain on Celmed's...
BioCentury | Apr 18, 2005
Company News

Chronogen management update

...as VP of corporate and business development, formerly VP of preclinical research and technologies at Celmed BioSciences Inc. WIR...
BioCentury | Jul 12, 2004
Company News

NewBiotics, Theratechnologies deal

...TH's majority-owned subsidiary, Celmed BioSciences Inc. (Montreal, Quebec), completed its previously announced acquisition of cancer company NewBiotics (see...
...June 14). NewBiotics shareholders received a 29.7% ownership interest in Celmed, and TH's ownership in Celmed...
BioCentury | Jun 14, 2004
Company News

NewBiotics, Theratechnologies deal

...TH's majority owned subsidiary, Celmed BioSciences Inc. (Montreal, Quebec), will acquire cancer company NewBiotics. NewBiotics shareholders will receive...
...shareholders will receive a 29.7% ownership interest in Celmed, which will reduce TH's ownership in Celmed...
...toxin by thymidylate synthase (TS) that is in Phase l/ll trials to treat colorectal cancer. Celmed...
BioCentury | Jun 7, 2004
Company News

Celmed to acquire NewBiotics

...Theratechnologies (TSE:TH) subsidiary Celmed BioSciences will acquire cancer company NewBiotics (San Diego, Calif.) in a stock...
...NewBiotics shareholders will receive a 29.7% ownership interest in Celmed , which will reduce TH's Celmed...
...Last month, Celmed sold its neurology assets to Dr. Michel Levesque of Cedars Sinai Hospital. Celmed...
BioCentury | May 3, 2004
Company News

Theratechnologies deal

...sold the neurology assets of Celmed USA to Dr. Michel Levesque of Cedars Sinai Hospital. Celmed...
BioCentury | Nov 24, 2003
Company News

Celmed management update

Celmed BioSciences Inc. , Montreal, Quebec Business: Gene/Cell therapy Promoted: Mark Kaufmann to COO while remaining VP of corporate development Hired: Pierre Caudrelier as VP of clinical affairs, formerly director of planning and analysis at MedImmune...
Items per page:
1 - 10 of 20
BioCentury | Dec 18, 2006
Company News

Celmed, Kiadis deal

...companies completed their previously announced merger to form Kiadis Pharma B.V. (see BioCentury, Dec. 4). Celmed Biosciences Inc....
BioCentury | Dec 4, 2006
Company News

Celmed, Kiadis deal

...Kiadis will acquire cancer company Celmed for an undisclosed amount of stock. Celmed's pipeline includes TH9402...
...its BioSelact screening technology to identify kinase inhibitors for cancer. Financial details were not disclosed. Celmed Biosciences Inc....
BioCentury | Feb 27, 2006
Company News

Celmed management update

Celmed BioSciences Inc. , Montreal, Quebec Business: Autoimmune, Cancer Promoted: Mark Kaufmann to president and CEO from COO and VP of corporate development Retired: Andre de Villers as president and CEO, while remaining a director WIR...
BioCentury | Feb 22, 2006
Company News

Celmed names Kaufmann CEO

...Cancer and autoimmune company Celmed (Montreal, Quebec) promoted Mark Kaufmann to president and CEO from COO...
...VP of corporate development. He replaces Andre de Villers, who retired but will remain on Celmed's...
BioCentury | Apr 18, 2005
Company News

Chronogen management update

...as VP of corporate and business development, formerly VP of preclinical research and technologies at Celmed BioSciences Inc. WIR...
BioCentury | Jul 12, 2004
Company News

NewBiotics, Theratechnologies deal

...TH's majority-owned subsidiary, Celmed BioSciences Inc. (Montreal, Quebec), completed its previously announced acquisition of cancer company NewBiotics (see...
...June 14). NewBiotics shareholders received a 29.7% ownership interest in Celmed, and TH's ownership in Celmed...
BioCentury | Jun 14, 2004
Company News

NewBiotics, Theratechnologies deal

...TH's majority owned subsidiary, Celmed BioSciences Inc. (Montreal, Quebec), will acquire cancer company NewBiotics. NewBiotics shareholders will receive...
...shareholders will receive a 29.7% ownership interest in Celmed, which will reduce TH's ownership in Celmed...
...toxin by thymidylate synthase (TS) that is in Phase l/ll trials to treat colorectal cancer. Celmed...
BioCentury | Jun 7, 2004
Company News

Celmed to acquire NewBiotics

...Theratechnologies (TSE:TH) subsidiary Celmed BioSciences will acquire cancer company NewBiotics (San Diego, Calif.) in a stock...
...NewBiotics shareholders will receive a 29.7% ownership interest in Celmed , which will reduce TH's Celmed...
...Last month, Celmed sold its neurology assets to Dr. Michel Levesque of Cedars Sinai Hospital. Celmed...
BioCentury | May 3, 2004
Company News

Theratechnologies deal

...sold the neurology assets of Celmed USA to Dr. Michel Levesque of Cedars Sinai Hospital. Celmed...
BioCentury | Nov 24, 2003
Company News

Celmed management update

Celmed BioSciences Inc. , Montreal, Quebec Business: Gene/Cell therapy Promoted: Mark Kaufmann to COO while remaining VP of corporate development Hired: Pierre Caudrelier as VP of clinical affairs, formerly director of planning and analysis at MedImmune...
Items per page:
1 - 10 of 20